Novo Nordisk said on Monday it is offering its diabetes drug Ozempic for $499 per month to eligible cash-paying type 2 ...

Eli Lilly and Novo Nordisk already make popular GLP-1s in the Triangle. A Swiss drugmaker says its future Wake County site will, too.

Eli Lilly and Company is making headlines with a staggering 170% price increase for its weight-loss drug, Mounjaro, in the UK ...

Eli Lilly and Company (NYSE: LLY) is one of the best stocks to invest in for long-term growth. Eli Lilly and Company ...

Eli Lilly's orforglipron could have a few advantages over a pill from Novo Nordisk, including a lack of dietary restrictions ...

Can Novo Nordisk and Eli Lilly regain their former stock market glory? A lot is riding on next year's pills ...

COMMENT: The monthly cost of a private prescription for Mounjaro is set to exceed £300 from next month – worrying news for ...

Through innovation, cost discipline, legal action, and competitive pricing, Novo Nordisk has reasserted its leadership in the GLP-1 market. With a robust pipeline and global expansion, NVO is poised ...

Mounjaro and other GLP-1 drugs may lower cancer risk in obese patients, according to a new study. Read more here.

In the wake of weight-loss drugs and the rising importance of health, the iconic cultural brand must double down on its roots ...

GLP-1 drugs for diabetes and weight loss may influence patients’ cancer risk, usually lowering it but sometimes possibly ...